Vor Biopharma Inc. (NYSE:VOR) Position Increased by RA Capital Management L.P.

RA Capital Management L.P. boosted its stake in shares of Vor Biopharma Inc. (NYSE:VOR - Free Report) by 74.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,646,039 shares of the company's stock after acquiring an additional 16,897,159 shares during the quarter. RA Capital Management L.P. owned 57.73% of Vor Biopharma worth $44,007,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Vor Biopharma in the fourth quarter worth approximately $60,000. Lynx1 Capital Management LP acquired a new position in Vor Biopharma in the fourth quarter valued at $707,000. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the 4th quarter valued at approximately $80,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Vor Biopharma during the fourth quarter worth about $33,000. Finally, Northern Trust Corp raised its stake in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after buying an additional 44,252 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Vor Biopharma Trading Down 8.6 %

NYSE VOR traded down $0.06 during trading hours on Monday, reaching $0.60. 337,810 shares of the company traded hands, compared to its average volume of 588,332. The company has a 50 day moving average of $0.77 and a two-hundred day moving average of $0.98. The stock has a market capitalization of $75.45 million, a PE ratio of -0.37 and a beta of -0.21. Vor Biopharma Inc. has a 12 month low of $0.49 and a 12 month high of $1.87.

Analyst Ratings Changes

Several brokerages recently weighed in on VOR. Stifel Nicolaus cut their target price on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. HC Wainwright reduced their price target on shares of Vor Biopharma from $17.50 to $13.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Wedbush reissued an "outperform" rating and issued a $7.00 target price on shares of Vor Biopharma in a research note on Thursday, March 20th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $8.86.

Vor Biopharma Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.